drugset
drugset / Trial / NCT01853722

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

NCT01853722 ↗

Phase 2 Completed 62 enrolled Deacon Biosciences, Inc. ORA, Inc. · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping of the periocular region.

Timeline

Start
2013-04
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DCN01 Unknown — Topical

Indications

eye infectious disorder